D. Quietzsch

1.3k total citations · 1 hit paper
30 papers, 1.1k citations indexed

About

D. Quietzsch is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, D. Quietzsch has authored 30 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Oncology, 17 papers in Pulmonary and Respiratory Medicine and 9 papers in Cancer Research. Recurrent topics in D. Quietzsch's work include Colorectal Cancer Treatments and Studies (15 papers), Pancreatic and Hepatic Oncology Research (12 papers) and Gastric Cancer Management and Outcomes (11 papers). D. Quietzsch is often cited by papers focused on Colorectal Cancer Treatments and Studies (15 papers), Pancreatic and Hepatic Oncology Research (12 papers) and Gastric Cancer Management and Outcomes (11 papers). D. Quietzsch collaborates with scholars based in Germany, Netherlands and Austria. D. Quietzsch's co-authors include Volker Heinemann, Michael Clemens, Andreas Schalhorn, Ursula Vehling‐Kaiser, Martin Fuchs, Caroline Haag, Axel Holstege, Horst Neuhaus, D. Uthgenannt and A. Rost and has published in prestigious journals such as Journal of Clinical Oncology, Journal of Clinical Epidemiology and British Journal of Cancer.

In The Last Decade

D. Quietzsch

29 papers receiving 1.0k citations

Hit Papers

Randomized Phase III Trial of Gemcitabine Plus Cisplatin ... 2006 2026 2012 2019 2006 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Randomized Phase III Trial of Gemcitabine Plus Cisplatin Compared With Gemcitabine Alone in Advanced Pancreatic Cancer
    2006 535 citations Volker Heinemann, D. Quietzsch et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
D. Quietzsch Germany 14 886 461 291 210 191 30 1.1k
N. Androulakis Greece 20 1.1k 1.3× 681 1.5× 290 1.0× 182 0.9× 124 0.6× 46 1.3k
Emmanuelle Samalin France 16 562 0.6× 353 0.8× 114 0.4× 201 1.0× 111 0.6× 75 827
H Schönekäs Germany 7 543 0.6× 252 0.5× 222 0.8× 223 1.1× 154 0.8× 11 691
B. Mirtsching United States 12 1.1k 1.3× 459 1.0× 288 1.0× 131 0.6× 136 0.7× 27 1.3k
Shannon McDonough United States 15 989 1.1× 262 0.6× 302 1.0× 180 0.9× 206 1.1× 35 1.2k
U. Fink Germany 13 402 0.5× 435 0.9× 106 0.4× 405 1.9× 105 0.5× 26 901
Shin Nakahira Japan 13 482 0.5× 246 0.5× 102 0.4× 387 1.8× 130 0.7× 61 724
D.G. Haller United States 12 539 0.6× 291 0.6× 63 0.2× 176 0.8× 173 0.9× 28 805
Giovanni Randon Italy 16 673 0.8× 361 0.8× 141 0.5× 183 0.9× 49 0.3× 51 915
Yuichi Arimoto Japan 13 376 0.4× 313 0.7× 165 0.6× 429 2.0× 59 0.3× 35 1.0k

Countries citing papers authored by D. Quietzsch

Since Specialization
Citations

This map shows the geographic impact of D. Quietzsch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by D. Quietzsch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites D. Quietzsch more than expected).

Fields of papers citing papers by D. Quietzsch

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by D. Quietzsch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by D. Quietzsch. The network helps show where D. Quietzsch may publish in the future.

Co-authorship network of co-authors of D. Quietzsch

This figure shows the co-authorship network connecting the top 25 collaborators of D. Quietzsch. A scholar is included among the top collaborators of D. Quietzsch based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with D. Quietzsch. D. Quietzsch is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
Heinemann, Volker, Laura Fischer, Frank Gieseler, et al.. (2023). Three-month life expectancy as inclusion criterion for clinical trials in advanced pancreatic cancer: is it really a valid tool for patient selection?. Clinical & Translational Oncology. 26(5). 1268–1272. 1 indexed citations
4.
Fottner, Christian, Harald Lahner, Henning Jann, et al.. (2022). Treatment Approaches and Outcome of Patients with Neuroendocrine Neoplasia Grade 3 in German Real-World Clinical Practice. Cancers. 14(11). 2718–2718. 5 indexed citations
5.
Stahler, Arndt, Volker Heinemann, Jens Neumann, et al.. (2017). Prevalence and influence on outcome of HER2/neu, HER3 and NRG1 expression in patients with metastatic colorectal cancer. Anti-Cancer Drugs. 28(7). 717–722. 14 indexed citations
6.
Ormanns, Steffen, Michael Haas, A. Altendorf-Hofmann, et al.. (2016). Impact of SPARC expression on outcome in patients with advanced pancreatic cancer not receiving nab-paclitaxel: a pooled analysis from prospective clinical and translational trials. British Journal of Cancer. 115(12). 1520–1529. 17 indexed citations
7.
Modest, Dominik Paul, Christoph Schulz, Ludwig Fischer von Weikersthal, et al.. (2013). Outcome of patients with metastatic colorectal cancer depends on the primary tumor site (midgut vs. hindgut). Anti-Cancer Drugs. 25(2). 212–218. 39 indexed citations
8.
Weikersthal, Ludwig Fischer von, Andreas Schalhorn, Martina Stauch, et al.. (2010). Phase III trial of irinotecan plus infusional 5-fluorouracil/folinic acid versus irinotecan plus oxaliplatin as first-line treatment of advanced colorectal cancer. European Journal of Cancer. 47(2). 206–214. 43 indexed citations
9.
Hartmann, Jörg T., Salah‐Eddin Al‐Batran, D. Quietzsch, et al.. (2007). Mitomycin C plus Infusional 5-Fluorouracil in Platinum-Refractory Gastric Adenocarcinoma: An Extended Multicenter Phase II Study. Oncology Research and Treatment. 30(5). 235–240. 10 indexed citations
10.
Fahlke, J., Karsten Ridwelski, E. Kettner, et al.. (2007). A Multicentre Phase II Study of Docetaxel plus Cisplatin for the Treatment of Advanced Gastric Cancer. Chemotherapy. 53(6). 454–460. 6 indexed citations
11.
Boeck, Stefan, K. Weigang-Köhler, Martin Fuchs, et al.. (2007). Second-line chemotherapy with pemetrexed after gemcitabine failure in patients with advanced pancreatic cancer: a multicenter phase II trial. Annals of Oncology. 18(4). 745–751. 59 indexed citations
12.
Fahrig, Rudolf, D. Quietzsch, Volker Heinemann, et al.. (2006). RP101 improves the efficacy of chemotherapy in pancreas carcinoma cell lines and pancreatic cancer patients. Anti-Cancer Drugs. 17(9). 1045–1056. 17 indexed citations
13.
Heinemann, Volker, D. Quietzsch, Frank Gieseler, et al.. (2006). Randomized Phase III Trial of Gemcitabine Plus Cisplatin Compared With Gemcitabine Alone in Advanced Pancreatic Cancer. Journal of Clinical Oncology. 24(24). 3946–3952. 535 indexed citations breakdown →
14.
Schalhorn, Andreas, D. Quietzsch, P. Maubach, et al.. (2005). Phase III trial of irinotecan plus oxaliplatin (IROX) versus irinotecan plus 5-FU/folinic acid (FOLFIRI) as first-line treatment of metastatic colorectal cancer (CRC): The FIRE-Trial. Journal of Clinical Oncology. 23(16_suppl). 3516–3516. 11 indexed citations
15.
Hartmann, Jakob, Karin Oechsle, D. Quietzsch, et al.. (2003). Protracted infusional 5-fluorouracil plus high-dose folinic acid combined with bolus mitomycin C in patients with gastrointestinal cancer: a phase I/II dose escalation study. British Journal of Cancer. 89(11). 2051–2056. 12 indexed citations
16.
Honecker, Friedemann, Christian Kollmannsberger, D. Quietzsch, et al.. (2002). Phase II study of weekly paclitaxel plus 24-h continuous infusion 5-fluorouracil, folinic acid and 3-weekly cisplatin for the treatment of patients with advanced gastric cancer. Anti-Cancer Drugs. 13(5). 497–503. 44 indexed citations
17.
Kollmannsberger, Christian, D. Quietzsch, Christian Haag, et al.. (2000). A phase II study of paclitaxel, weekly, 24-hour continuous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer. British Journal of Cancer. 83(4). 458–462. 101 indexed citations
18.
Hartmann, J.T., D. Quietzsch, Thomas Daikeler, et al.. (1999). Mitomycin C continuous infusion as salvage chemotherapy in pretreated patients with advanced gastric cancer. Anti-Cancer Drugs. 10(8). 729–734. 20 indexed citations
19.
Heinemann, Lothar, et al.. (1998). Entwicklung der Herz-Kreislauf-Morbidität und -Mortalität in Ostdeutschland nach der politisch-ökonomischen Wende. Journal of Public Health. 6(2). 120–136. 5 indexed citations
20.
Löwel, Hannelore, Michael A. O. Lewis, B. Herman, et al.. (1996). Coronary heart disease mortality, morbidity, and case fatality in five east and West German cities 1985–1989. Journal of Clinical Epidemiology. 49(11). 1277–1284. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by N. Androulakis Breakdown of academic impact, for papers by Emmanuelle Samalin Breakdown of academic impact, for papers by H Schönekäs Breakdown of academic impact, for papers by B. Mirtsching Breakdown of academic impact, for papers by Shannon McDonough Breakdown of academic impact, for papers by U. Fink Breakdown of academic impact, for papers by Shin Nakahira Breakdown of academic impact, for papers by D.G. Haller Breakdown of academic impact, for papers by Giovanni Randon Breakdown of academic impact, for papers by Yuichi Arimoto
Rankless by CCL
2026